Aldeyra Therapeutics (ALDX) Competitors $5.78 -0.04 (-0.60%) Closing price 03:59 PM EasternExtended Trading$5.76 -0.01 (-0.17%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALDX vs. PAHC, XERS, CVAC, ELVN, CALT, COLL, NTLA, PHVS, GPCR, and TLRYShould you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Phibro Animal Health (PAHC), Xeris Biopharma (XERS), CureVac (CVAC), Enliven Therapeutics (ELVN), Calliditas Therapeutics AB (publ) (CALT), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), Pharvaris (PHVS), Structure Therapeutics (GPCR), and Tilray Brands (TLRY). These companies are all part of the "pharmaceutical products" industry. Aldeyra Therapeutics vs. Its Competitors Phibro Animal Health Xeris Biopharma CureVac Enliven Therapeutics Calliditas Therapeutics AB (publ) Collegium Pharmaceutical Intellia Therapeutics Pharvaris Structure Therapeutics Tilray Brands Phibro Animal Health (NASDAQ:PAHC) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Which has higher valuation and earnings, PAHC or ALDX? Phibro Animal Health has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhibro Animal Health$1.19B1.09$2.42M$0.7841.01Aldeyra TherapeuticsN/AN/A-$55.85M-$0.85-6.79 Does the media refer more to PAHC or ALDX? In the previous week, Phibro Animal Health had 12 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 16 mentions for Phibro Animal Health and 4 mentions for Aldeyra Therapeutics. Phibro Animal Health's average media sentiment score of 0.62 beat Aldeyra Therapeutics' score of 0.49 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aldeyra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in PAHC or ALDX? 99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, PAHC or ALDX? Phibro Animal Health has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Is PAHC or ALDX more profitable? Phibro Animal Health has a net margin of 2.68% compared to Aldeyra Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 30.51% beat Aldeyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Phibro Animal Health2.68% 30.51% 6.89% Aldeyra Therapeutics N/A -73.63%-50.61% Do analysts rate PAHC or ALDX? Phibro Animal Health currently has a consensus target price of $24.40, indicating a potential downside of 23.71%. Aldeyra Therapeutics has a consensus target price of $9.50, indicating a potential upside of 64.50%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 2 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.83Aldeyra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryPhibro Animal Health beats Aldeyra Therapeutics on 12 of the 15 factors compared between the two stocks. Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALDX vs. The Competition Export to ExcelMetricAldeyra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$345.92M$2.78B$5.75B$9.73BDividend YieldN/A1.67%4.40%4.10%P/E Ratio-6.7922.2430.2525.89Price / SalesN/A749.20474.39123.10Price / CashN/A26.0925.7828.79Price / Book4.855.539.426.00Net Income-$55.85M$31.83M$3.27B$265.29M7 Day Performance6.16%1.07%2.08%2.59%1 Month Performance11.70%0.83%3.63%0.98%1 Year Performance3.68%7.24%30.13%18.75% Aldeyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALDXAldeyra Therapeutics1.8471 of 5 stars$5.78-0.6%$9.50+64.5%+4.3%$345.92MN/A-6.7910PAHCPhibro Animal Health3.4317 of 5 stars$31.25+1.9%$24.40-21.9%+55.0%$1.24B$1.19B40.061,940News CoverageUpcoming EarningsXERSXeris Biopharma3.4214 of 5 stars$7.36-4.2%$6.58-10.6%+169.1%$1.24B$203.07M-35.05290News CoveragePositive NewsAnalyst RevisionCVACCureVac4.6409 of 5 stars$5.45-0.5%$6.83+25.4%+64.4%$1.23B$579.18M5.92880Earnings ReportELVNEnliven Therapeutics2.8149 of 5 stars$19.75-2.3%$41.20+108.6%-9.3%$1.20BN/A-9.8850CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180COLLCollegium Pharmaceutical3.1065 of 5 stars$38.19+1.2%$42.33+10.8%+7.9%$1.19B$631.45M36.72210News CoveragePositive NewsNTLAIntellia Therapeutics4.6079 of 5 stars$10.73-2.4%$29.05+170.8%-55.5%$1.18B$57.88M-2.29600Positive NewsInsider TradeGap UpPHVSPharvaris2.9556 of 5 stars$22.16-0.6%$35.60+60.6%+29.5%$1.17BN/A-6.6030Positive NewsGPCRStructure Therapeutics2.4541 of 5 stars$19.96-0.8%$75.71+279.3%-50.7%$1.16BN/A-19.01136TLRYTilray Brands2.4868 of 5 stars$1.14+10.7%$1.92+68.1%-40.4%$1.13B$821.31M-0.492,842Analyst ForecastGap Up Related Companies and Tools Related Companies PAHC Competitors XERS Competitors CVAC Competitors ELVN Competitors CALT Competitors COLL Competitors NTLA Competitors PHVS Competitors GPCR Competitors TLRY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALDX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access